Search Results for Boehringer Ingelheim

Showing 1 – 5

Boehringer Questions FDA's Draft Guidance on Optional Child-Resistant Packaging Statements By Zachary Brennan - Published 10 October 2017

Boehringer Ingelheim has questions on how new US Food and Drug Administration (FDA) draft guidance on optional child-resistant packaging (CRP) statements will benefit health care professionals and consumers.

Categories: News, US, FDA, Drugs, Labeling, Packaging

Tags: child-resistant packaging, Boehringer Ingelheim, FDA draft guidance

Asia Regulatory Roundup: CFDA Expands Trial Data Quality Monitoring Drive to Cover Medical Devices (11 July 2017) By Nick Paul Taylor - Published 11 July 2017

Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia.

Categories: News, Asia, Oceania, CFDA, Medsafe, TGA, Biologics and biotechnology, Drugs, Medical Devices

Tags: Asia Regulatory Roundup, J&J, Boehringer Ingelheim

Boehringer Ingelheim Warns MHRA of Reckitt Benckiser’s Misleading TV Advertisement By Zachary Brennan - Published 06 June 2016

It’s well known that competition among pharmaceutical companies is fierce, and a misstep, usually in a clinical trial, can result in millions, if not billions of dollars lost. And now a glimpse of that competition is boiling over into the realm of television advertising.

Categories: News, Europe, MHRA, Advertising and Promotion, Over the counter drugs

Tags: Senokot, Reckitt Benckiser, Boehringer Ingelheim, Dulcolax, laxative, OTC drug television advertisements

Government Watchdog: FDA Took 'Lax or Permissive' Approach to Pradaxa Approval By Zachary Brennan - Published 15 October 2015

The US Food and Drug Administration's (FDA) judgments regarding the clinical trial and approval of Boehringer Ingelheim's blood thinner Pradaxa (dabigatran) reveal "a lax or permissive approach," according to a new report from the Project On Government Oversight (POGO).

Categories: News, US, FDA, Drugs, Due Diligence, Postmarket surveillance, Regulatory intelligence, Regulatory strategy, Research and development

Tags: FDA, Pradaxa, Boehringer Ingelheim, POGO

Boehringer Ingelheim's Blot Clot Drug Cleared for NHS Use By Louise Zornoza, RegLink - Published 28 September 2012

Categories: Regulatory Update, NICE

Tags: Boehringer Ingelheim, Stroke, NHS, guidance